How much revenue does Oncodesign Precision Medicine Société anonyme make?

Oncodesign Precision Medicine Société anonyme reported 261,148 EUR in revenue for fiscal year 2025, up 26.1% from 207,040 EUR in fiscal year 2024.

What companies are similar to Oncodesign Precision Medicine Société anonyme?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Ipsen S.a. (IPN.PA), Valerio Therapeutics Société anonyme (ALVIO.PA), Transgene SA (TNG.PA).

Oncodesign Precision Medicine Société anonyme (ALOPM.PA) Stock

About Oncodesign Precision Medicine Société anonyme

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radi...

At a glance

Oncodesign Precision Medicine Société anonyme reported revenue of 261,148 EUR for fiscal year 2025, up 26.1% from fiscal year 2024, and net income of 5.48 million EUR.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.